Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver ...

PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, ...

-- 11 new abstracts including MASH data to be presented at the 76th Annual AASLD The Liver Meeting (R), 7-11 November -- Highlights include data from post-hoc analyses of the ESSENCE trial ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a ...

MASH data to be presented at the 76th Annual AASLD The Liver Meeting®, 7-11 November Highlights include data from post-hoc analyses ...

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of ...

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it ...

The annual meeting of the American College of Gastroenterology was held from Oct. 24 to 29 in Phoenix, attracting participants from around the world, including gastroenterology and digestive disease ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Novo Nordisk to present 11 abstracts at the 76th Annual American Association for Study of Liver Diseases congress: Denmark Friday, October 31, 2025, 15:00 Hrs [IST] Novo Nordisk h ...